Orthomyxoviridae Infections - Pipeline Review, H2 2012

Global Markets Direct, August 2012, Pages: 250

Orthomyxoviridae Infections – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Orthomyxoviridae Infections - Pipeline Review, H2 2012', provides an overview of the Orthomyxoviridae Infections therapeutic pipeline. This report provides information on the therapeutic development for Orthomyxoviridae Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Orthomyxoviridae Infections. 'Orthomyxoviridae Infections - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Orthomyxoviridae Infections.
- A review of the Orthomyxoviridae Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Orthomyxoviridae Infections pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Orthomyxoviridae Infections.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Orthomyxoviridae Infections pipeline depth and focus of Orthomyxoviridae Infections therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Orthomyxoviridae Infections Therapeutic Products under Development, Key Players in Orthomyxoviridae Infections Therapeutics, Orthomyxoviridae Infections Pipeline Overview, Orthomyxoviridae Infections Pipeline, Orthomyxoviridae Infections Pipeline Assessment

2
List of Tables 7
List of Figures 11
Introduction 12
REPORT COVERAGE 12
Orthomyxoviridae Infections Overview 13
Therapeutics Development 14
An Overview of Pipeline Products for Orthomyxoviridae Infections 14
Orthomyxoviridae Infections Therapeutics under Development by Companies 16
Orthomyxoviridae Infections Therapeutics under Investigation by Universities/Institutes 26
Late Stage Products 30
Comparative Analysis 30
Mid Clinical Stage Products 31
Comparative Analysis 31
Early Clinical Stage Products 32
Comparative Analysis 32
Discovery and Pre-Clinical Stage Products 33
Comparative Analysis 33
Orthomyxoviridae Infections Therapeutics – Products under Development by Companies 34
Orthomyxoviridae Infections Therapeutics – Products under Investigation by Universities/Institutes 48
Companies Involved in Orthomyxoviridae Infections Therapeutics Development 52
Baxter International Inc. 52
Johnson & Johnson 53
Vical Incorporated 54
Sanofi-Aventis 55
AstraZeneca PLC 56
GlaxoSmithKline plc 57
Inovio Biomedical Corporation 58
MedImmune LLC 59
Daiichi Sankyo Company, Ltd 60
Emergent BioSolutions Inc. 61
Lentigen Corporation 62
Generex Biotechnology Corporation 63
Ceragenix Pharmaceuticals, Inc. 64
Celltrion, Inc. 65
Nanotherapeutics, Inc. 66
Liquidia Technologies, Inc. 67
Ambrilia Biopharma Inc. 68
Novartis AG 69
Aphios Corporation 70
MDRNA, Inc. 71
Novavax, Inc. 72
Toyama Chemical Co. Ltd 73
Vertex Pharmaceuticals Incorporated 74
CEL-SCI Corporation 75
AVI BioPharma Inc. 76
Crucell N.V. 77
OPKO Health, Inc. 78
Zosano Pharma, Inc. 79
4SC AG 80
Hemispherx Biopharma, Inc. 81
Intercell AG 82
Medicago Inc. 83
BioDiem Ltd 84
Biota Holdings Limited 85
Mymetics Corporation 86
NanoViricides, Inc. 87
NovaBay Pharmaceuticals, Inc. 88
Oramed Pharmaceuticals, Inc. 89
Pevion Biotech Ltd 90
CytoGenix, Inc. 91
Amarillo Biosciences, Inc. 92
BioCryst Pharmaceuticals, Inc. 93
Dynavax Technologies Corporation 94
XOMA Ltd. 95
Immuron Limited 96
Lipoxen PLC 97
Green Cross Corporation 98
Cytos Biotechnology AG 99
Synairgen plc 100
Panacea Biotec Limited 101
Eurocine Vaccines AB 102
Antigen Express, Inc. 103
Functional Genetics, Inc. 104
Colby Pharmaceutical Company 105
Avanti Therapeutics 106
Marinomed Biotechnologie GmbH 107
Nutri Pharma ASA 108
LigoCyte Pharmaceuticals, Inc. 109
Evolva SA 110
Vironova AB 111
ImmunoBiology Limited 112
CureVac GmbH 113
TechnoVax, Inc. 114
MacroGenics, Inc. 115
Pulmatrix, Inc. 116
Okairos 117
Viroblock S.A. 118
AlphaVax, Inc. 119
Innate Therapeutics Limited 120
Vaxin, Inc. 121
EpiVax, Inc. 122
Indus Biotech Private Limited 123
Romark Laboratories, L.C. 124
Adamas Pharmaceuticals, Inc. 125
Theraclone Sciences, Inc. 126
REPLICor Inc. 127
Immune Targeting Systems (ITS) Ltd. 128
Sinovac Biotech Ltd. 129
Exponential Biotherapies, Inc. 130
NanoBio Corporation 131
Protein Sciences Corporation 132
ImmunoVaccine Technologies Inc. 133
VaxInnate Corporation 134
Etubics Corporation 135
Obio Pharmaceutical Holdings Limited. 136
Canopus BioPharma Incorporated 137
iBio, Inc. 138
PepTcell Limited 139
BiondVax Pharmaceuticals Ltd. 140
Arisyn Therapeutics Inc. 141
Avir Green Hills Biotechnology AG 142
Sirnaomics, Inc. 143
Vaxart, Inc. 144
Hawaii Biotech, Inc. 145
Variation Biotechnologies, Inc. 146
IRX Therapeutics, Inc. 147
NexBio, Inc. 148
NasVax Ltd. 149
ImmuneRegen BioSciences, Inc. 150
Trellis Bioscience, Inc. 151
Selecta Biosciences, Inc. 152
Inviragen, Inc. 153
PaxVax 154
Denka Seiken Co., Ltd. 155
AmVac AG 156
Vivaldi Biosciences Inc. 157
Vaxine Pty Ltd 158
APEPTICO Forschung und Entwicklung GmbH 159
VLP Biotech, Inc. 160
UNeMed 161
Clarassance, Inc. 162
Orthomyxoviridae Infections – Therapeutics Assessment 163
Assessment by Monotherapy Products 163
Assessment by Combination Products 164
Assessment by Route of Administration 165
Assessment by Molecule Type 167
Drug Profiles 169
Q-LAIV Flu Vac - Drug Profile 169
Q-LAIV Flu Vac - Drug Profile 170
T-705 - Drug Profile 171
Peramivir - Drug Profile 172
NT-300 - Drug Profile 174
Inavir - Drug Profile 175
FluBlok - Drug Profile 177
FluBlok - Drug Profile 179
Whole Virus H5N1 Influenza Vaccine - Drug Profile 181
Cholecalciferol - Drug Profile 182
GSK2340269A - Drug Profile 183
H1N1 Influenza Vaccine - Drug Profile 185
GSK2340272A - Drug Profile 187
H1N1 Influenza Vaccine - Drug Profile 189
Fluviral - Drug Profile 190
GSK2321138A - Drug Profile 191
GSK2321138A - Drug Profile 192
GSK2340273A - Drug Profile 193
Optaflu - Drug Profile 195
Resfenol - Drug Profile 196
Relenza - Drug Profile 198
Zanamivir - Drug Profile 200
Vaxigrip - Drug Profile 201
Flu (pre-) Pandemic - Drug Profile 202
Preflucel - Drug Profile 204
Flu Vaccine - Drug Profile 205
Inactivated Split-virion Influenza A(H1N1) Vaccine GC1116 - Drug Profile 206
Oseltamivir - Drug Profile 207
MF59C.1 Adjuvanted Trivalent Subunit Influenza Vaccine - Drug Profile 208
Fluad - Drug Profile 210
MF59-eH1N1 Influenza Vaccine - Drug Profile 211
Mutagrip - Drug Profile 212
Monovalent A/H1N1 Influenza Vaccine - Drug Profile 213
Fluzone QIV Vaccine - Drug Profile 215
Vaxigrip QIV IM - Drug Profile 217
Orthomyxoviridae Infections Therapeutics – Drug Profile Updates 218
Orthomyxoviridae Infections Therapeutics – Discontinued Products 228
Orthomyxoviridae Infections Therapeutics - Dormant Products 230
Orthomyxoviridae Infections – Product Development Milestones 239
Featured News & Press Releases 239
Appendix 247
Methodology 247
Coverage 247
Secondary Research 247
Primary Research 247
Expert Panel Validation 247
Contact Us 248
Disclaimer 248

List of Tables
Number of Products Under Development for Orthomyxoviridae Infections, H2 2012 16
Products under Development for Orthomyxoviridae Infections – Comparative Analysis, H2 2012 17
Number of Products under Development by Companies, H2 2012 19
Number of Products under Development by Companies, H2 2012 (Contd..1) 20
Number of Products under Development by Companies, H2 2012 (Contd..2) 21
Number of Products under Development by Companies, H2 2012 (Contd..3) 22
Number of Products under Development by Companies, H2 2012 (Contd..4) 23
Number of Products under Development by Companies, H2 2012 (Contd..5) 24
Number of Products under Development by Companies, H2 2012 (Contd..6) 25
Number of Products under Development by Companies, H2 2012 (Contd..7) 26
Number of Products under Development by Companies, H2 2012 (Contd..8) 27
Number of Products under Investigation by Universities/Institutes, H2 2012 29
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 30
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 31
Comparative Analysis by Late Stage Development, H2 2012 32
Comparative Analysis by Mid Clinical Stage Development, H2 2012 33
Comparative Analysis by Early Clinical Stage Development, H2 2012 34
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 35
Products under Development by Companies, H2 2012 36
Products under Development by Companies, H2 2012 (Contd..1) 37
Products under Development by Companies, H2 2012 (Contd..2) 38
Products under Development by Companies, H2 2012 (Contd..3) 39
Products under Development by Companies, H2 2012 (Contd..4) 40
Products under Development by Companies, H2 2012 (Contd..5) 41
Products under Development by Companies, H2 2012 (Contd..6) 42
Products under Development by Companies, H2 2012 (Contd..7) 43
Products under Development by Companies, H2 2012 (Contd..8) 44
Products under Development by Companies, H2 2012 (Contd..9) 45
Products under Development by Companies, H2 2012 (Contd..10) 46
Products under Development by Companies, H2 2012 (Contd..11) 47
Products under Development by Companies, H2 2012 (Contd..12) 48
Products under Development by Companies, H2 2012 (Contd..13) 49
Products under Investigation by Universities/Institutes, H2 2012 50
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 51
Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 52
Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 53
Baxter International Inc., H2 2012 54
Johnson & Johnson, H2 2012 55
Vical Incorporated, H2 2012 56
Sanofi-Aventis, H2 2012 57
AstraZeneca PLC, H2 2012 58
GlaxoSmithKline plc, H2 2012 59
Inovio Biomedical Corporation, H2 2012 60
MedImmune LLC, H2 2012 61
Daiichi Sankyo Company, Ltd, H2 2012 62
Emergent BioSolutions Inc., H2 2012 63
Lentigen Corporation, H2 2012 64
Generex Biotechnology Corporation, H2 2012 65
Ceragenix Pharmaceuticals, Inc., H2 2012 66
Celltrion, Inc., H2 2012 67
Nanotherapeutics, Inc., H2 2012 68
Liquidia Technologies, Inc., H2 2012 69
Ambrilia Biopharma Inc., H2 2012 70
Novartis AG, H2 2012 71
Aphios Corporation, H2 2012 72
MDRNA, Inc., H2 2012 73
Novavax, Inc., H2 2012 74
Toyama Chemical Co. Ltd, H2 2012 75
Vertex Pharmaceuticals Incorporated, H2 2012 76
CEL-SCI Corporation, H2 2012 77
AVI BioPharma Inc., H2 2012 78
Crucell N.V., H2 2012 79
OPKO Health, Inc., H2 2012 80
Zosano Pharma, Inc., H2 2012 81
4SC AG, H2 2012 82
Hemispherx Biopharma, Inc., H2 2012 83
Intercell AG, H2 2012 84
Medicago Inc., H2 2012 85
BioDiem Ltd, H2 2012 86
Biota Holdings Limited, H2 2012 87
Mymetics Corporation, H2 2012 88
NanoViricides, Inc., H2 2012 89
NovaBay Pharmaceuticals, Inc., H2 2012 90
Oramed Pharmaceuticals, Inc., H2 2012 91
Pevion Biotech Ltd, H2 2012 92
CytoGenix, Inc., H2 2012 93
Amarillo Biosciences, Inc., H2 2012 94
BioCryst Pharmaceuticals, Inc., H2 2012 95
Dynavax Technologies Corporation, H2 2012 96
XOMA Ltd., H2 2012 97
Immuron Limited, H2 2012 98
Lipoxen PLC, H2 2012 99
Green Cross Corporation, H2 2012 100
Cytos Biotechnology AG, H2 2012 101
Synairgen plc, H2 2012 102
Panacea Biotec Limited, H2 2012 103
Eurocine Vaccines AB, H2 2012 104
Antigen Express, Inc., H2 2012 105
Functional Genetics, Inc., H2 2012 106
Colby Pharmaceutical Company, H2 2012 107
Avanti Therapeutics, H2 2012 108
Marinomed Biotechnologie GmbH, H2 2012 109
Nutri Pharma ASA, H2 2012 110
LigoCyte Pharmaceuticals, Inc., H2 2012 111
Evolva SA, H2 2012 112
Vironova AB, H2 2012 113
ImmunoBiology Limited, H2 2012 114
CureVac GmbH, H2 2012 115
TechnoVax, Inc., H2 2012 116
MacroGenics, Inc., H2 2012 117
Pulmatrix, Inc., H2 2012 118
Okairos, H2 2012 119
Viroblock S.A., H2 2012 120
AlphaVax, Inc., H2 2012 121
Innate Therapeutics Limited, H2 2012 122
Vaxin, Inc., H2 2012 123
EpiVax, Inc., H2 2012 124
Indus Biotech Private Limited, H2 2012 125
Romark Laboratories, L.C., H2 2012 126
Adamas Pharmaceuticals, Inc., H2 2012 127
Theraclone Sciences, Inc., H2 2012 128
REPLICor Inc., H2 2012 129
Immune Targeting Systems (ITS) Ltd., H2 2012 130
Sinovac Biotech Ltd., H2 2012 131
Exponential Biotherapies, Inc., H2 2012 132
NanoBio Corporation, H2 2012 133
Protein Sciences Corporation, H2 2012 134
ImmunoVaccine Technologies Inc., H2 2012 135
VaxInnate Corporation, H2 2012 136
Etubics Corporation, H2 2012 137
Obio Pharmaceutical Holdings Limited., H2 2012 138
Canopus BioPharma Incorporated, H2 2012 139
iBio, Inc., H2 2012 140
PepTcell Limited, H2 2012 141
BiondVax Pharmaceuticals Ltd., H2 2012 142
Arisyn Therapeutics Inc., H2 2012 143
Avir Green Hills Biotechnology AG, H2 2012 144
Sirnaomics, Inc., H2 2012 145
Vaxart, Inc., H2 2012 146
Hawaii Biotech, Inc., H2 2012 147
Variation Biotechnologies, Inc., H2 2012 148
IRX Therapeutics, Inc., H2 2012 149
NexBio, Inc., H2 2012 150
NasVax Ltd., H2 2012 151
ImmuneRegen BioSciences, Inc., H2 2012 152
Trellis Bioscience, Inc., H2 2012 153
Selecta Biosciences, Inc., H2 2012 154
Inviragen, Inc., H2 2012 155
PaxVax, H2 2012 156
Denka Seiken Co., Ltd., H2 2012 157
AmVac AG, H2 2012 158
Vivaldi Biosciences Inc., H2 2012 159
Vaxine Pty Ltd, H2 2012 160
APEPTICO Forschung und Entwicklung GmbH, H2 2012 161
VLP Biotech, Inc., H2 2012 162
UNeMed, H2 2012 163
Clarassance, Inc., H2 2012 164
Assessment by Monotherapy Products, H2 2012 165
Assessment by Combination Products, H2 2012 166
Assessment by Stage and Route of Administration, H2 2012 168
Assessment by Stage and Molecule Type, H2 2012 170
Orthomyxoviridae Infections Therapeutics – Drug Profile Updates 220
Orthomyxoviridae Infections Therapeutics – Discontinued Products 230
Orthomyxoviridae Infections Therapeutics – Discontinued Products (Contd..1) 231
Orthomyxoviridae Infections Therapeutics – Dormant Products 232
Orthomyxoviridae Infections Therapeutics – Dormant Products (Contd..1) 233
Orthomyxoviridae Infections Therapeutics – Dormant Products (Contd..2) 234
Orthomyxoviridae Infections Therapeutics – Dormant Products (Contd..3) 235
Orthomyxoviridae Infections Therapeutics – Dormant Products (Contd..4) 236
Orthomyxoviridae Infections Therapeutics – Dormant Products (Contd..5) 237
Orthomyxoviridae Infections Therapeutics – Dormant Products (Contd..6) 238
Orthomyxoviridae Infections Therapeutics – Dormant Products (Contd..7) 239
Orthomyxoviridae Infections Therapeutics – Dormant Products (Contd..8) 240

List of Figures
Number of Products under Development for Orthomyxoviridae Infections, H2 2012 16
Products under Development for Orthomyxoviridae Infections – Comparative Analysis, H2 2012 17
Products under Development by Companies, H2 2012 18
Products under Investigation by Universities/Institutes, H2 2012 28
Late Stage Products, H2 2012 32
Mid Clinical Stage Products, H2 2012 33
Early Clinical Stage Products, H2 2012 34
Discovery and Pre-Clinical Stage Products, H2 2012 35
Assessment by Monotherapy Products, H2 2012 165
Assessment by Combination Products, H2 2012 166
Assessment by Route of Administration, H2 2012 167
Assessment by Stage and Route of Administration, H2 2012 168
Assessment by Molecule Type, H2 2012 169
Assessment by Stage and Molecule Type, H2 2012 170

Customers who bought this item also bought

• Fungal Infections – Pipeline Review, H1 2013
• HIV / AIDS – Pipeline Review, H1 2013
• Ebola Viral Infections – Pipeline Review, H1 2013
• Alzheimer's Disease – Pipeline Review, H1 2013
• HIV-1 Infection – Pipeline Review, H1 2013
• Chemotherapy Effects – Pipeline Review, H1 2013
• Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline Review, H1 2013
• Lung Infections – Pipeline Review, H1 2013
• Stroke – Pipeline Review, H1 2013
• Major Depressive Disorder – Pipeline Review, H1 2013